ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting

Nov.24.2025

The U.S. FDA has scheduled a Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review Swedish Match USA’s Modified Risk Tobacco Product (MRTP) applications for 20 ZYN nicotine pouch products. Although the products gained PMTA authorization in early 2025, MRTP approval is required for marketing them with reduced-risk claims.

Key Points

TPSAC will review MRTP applications for 20 ZYN nicotine pouch products.
Company proposes the claim:“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
FDA has begun substantive scientific review; applications are open for public comment.
MRTP authorization requires evidence of reduced individual harm and population-level benefit.
Public comments accepted via Docket No. FDA-2025-N-0835 until January 21, 2026.
Requests to provide oral comments must be submitted by December 31, 2025.
Meeting will be virtual and publicly accessible.

2Firsts, November 24, 2025 — According to the U.S. Food and Drug Administration (FDA), a virtual meeting of the Tobacco Products Scientific Advisory Committee (TPSAC) will be held on January 22, 2026, to evaluate the Modified Risk Tobacco Product (MRTP) applications submitted by Swedish Match USA, Inc. for 20 ZYN nicotine pouch products.

The MRTP review covers 10 flavors in two strengths (3 mg and 6 mg):

ZYN Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen.

These products received PMTA authorization in January 2025, but marketing them with reduced-risk claims requires separate MRTP approval.

The proposed claim is:

“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

FDA notes that MRTP applications must demonstrate reduced harm under actual use conditions and show a net population health benefit.

By law, MRTP applications must undergo TPSAC review. The committee will evaluate:

Relative health risk evidence
Consumer understanding of the proposed claim
Potential public health impact of a modified risk order

The session will be virtual and open to the public with captioning and recording available.

Public comments may be submitted to Docket No. FDA-2025-N-0835 until 11:59 p.m. ET on January 21, 2026.

Comments submitted by January 7 will be forwarded to the committee.

Individuals wishing to provide oral comments must apply by 12 p.m. ET on December 31, 2025, with a summary of their intended remarks and participant information.

FDA also published redacted application materials for public review. Final MRTP determinations will incorporate all scientific evidence, public comments, and TPSAC recommendations.

Image source: FDA

References:

[1] Advisory Committee Meeting Scheduled on Modified Risk Tobacco Product Applications for ZYN Nicotine Pouch Products

Also Read:

[1] Trump Signs H.R.5371: FDA to Deploy $200 Million for ENDS Enforcement

[2] U.S FDA Announces Dec. 8 Deadline for IQOS MRTP Renewal Comments

[3] U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com